Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/12/2014 - 04/29/2017

This course is closed. Please look for other available products in CPNP University.

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Three new oral agents, fingolimod, teriflunomide, and dimethyl fumarate, have been approved for multiple sclerosis (MS) in the past four years. They carry unique mechanisms of action and adverse effects. This session reviews the efficacy and safety of these agents in detail, then discusses their role in the current landscape of MS therapy. All available agents will be compared with regard to route of administration, efficacy, adverse effects, and costs. Different treatment strategies, including sequential monotherapy, induction and maintenance, and combination therapy will also be discussed.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Melody Ryan, PharmD, MPH, BCPS, CGP, FCCP, FAPhA

View biographical information and disclosures

Learning Objectives

  1. Discuss the efficacy and safety of new drug therapies for the treatment of relapsing remitting multiple sclerosis (MS).
  2. Define measureable goals of disease modification therapy in MS.
  3. Discuss the role of available drugs for treatment of MS.
  4. Discuss the advantages and disadvantages of drugs for MS.

Continuing Education Credit and Disclosures

Activity Dates: 06/12/2014 - 04/29/2017
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-14-023-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit. The ACPE universal program number assigned to this course is 0284-0000-14-023-H01-P (1.0 contact hours).